Table 1.
Clinical symptoms before and after COVID-19 symptom onset.
| PGA (0–10 cm) |
PPGA (0–10 cm) |
Flares/3 Months | Fever | Rash | Fatigue | Dyspnea | Arthralgia | |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | ||||||||
| Before COVID-19 | 2 | 2 | 1 | - | - | + | - | + |
| ~Day 40 * | 2 | n.a. | n.a. | - | - | +++ | ++ | + |
| ~Day 100 * | 2 | n.a | n.a. | - | - | ++ | + | + |
| Patient 2 | ||||||||
| Before COVID-19 | ≤2 | ≤2 | 0 | - | - | - | - | - |
| Day 40 * | 2 | 5 | n.a | - | + | +/++ | - | - |
| Day 100 * | 2 | 2 | 1 | - | + | + | - | - |
| Patient 3 | ||||||||
| Before COVID-19 | 1–3 | 2 | 0 | - | - | + | - | - |
| Day 40 * | 4 | 7 | n.a. | - | ++ | +++ | - | + |
| Day 100 *,1 | 5 | 7 | 3 | +/++ | - | +++ | - | ++ |
| Patient 4 | ||||||||
| Before COVID-19 | ≤2 | 0 | 0 | - | - | - | - | - |
| Day 40 * | 2 | n.a. | n.a. | - | - | - | - | + |
| Day 100 * | 1 | 0 | 0 | - | - | - | - | - |
Abbreviations: PGA: physician global assessment recorded on a visual analog scale with 0= no disease activity and 10= maximum disease activity; PPGA: Disease activity estimated by the patient similar recorded to the PGA; n.a.: not available, Symptom severity: - absence, + mild, ++ moderate, +++ severe; * after COVID-19 onset; 1 five days after Canakinumab increase (300 mg/q4w).